Trial · NCT05572229
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
NCT05572229, Phase 2, Active not recruiting, University Hospital, Lille
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma. Trials, record NCT05572229. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05572229
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
- NCT number
- NCT05572229
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 74 participants, estimated
- Lead sponsor
- University Hospital, Lille
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab, Daratumumab, Lenalidomide
- First posted
- 2022-10-07
- Last updated
- 2026-09-25
- Other registries' IDs
- eudract:2022-001594-31
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len | At the end of 4 th cycle (each cycle is 28 days), an average 4 months | |
| Secondary | Treatment-emergent adverse events according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 5.0). | From date of randomization until the date of first documented progression,assessed up to 5 years | |
| Secondary | Overall response rate(PR or better) as defined by the IMWG response criteria | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years | |
| Secondary | Very good partial response or better, defined as VGPR or CR according to the IMWG criteria at the time of data cutoff | TFrom date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years | |
| Secondary | Complete response or better, defined as negative immunofixation of serum and urine, and disappearance of any soft tissue plasmacytomas, and <5% plasma cells in bone marrow* | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years | |
| Secondary | Time to response | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years | |
| Secondary | Duration of response | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years | |
| Secondary | Time from randomization to discontinuation of therapy for any reason including death, progression or toxicity | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years | |
| Secondary | Overall survival time | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years | OS, measured from the date of the first dose of study treatment to the date of the patient's death. If the patient is alive or the vital status is unknown at last contact, then the patient's data will be censored at the date the patient was last known to be alive |
| Secondary | TTTF, defined as the time from the date of the first dose of study treatment to discontinuation of therapy for any reason including death, progression, toxicity | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05572229
GET https://conductscience.org/api/trials/v1/NCT05572229/registered